GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Oncology/T1 CRC and ESD(GIE, Jan-2026)
118

T1 CRC and ESD(GIE, Jan-2026)

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated January 1, 2026

T1 Colorectal Cancer (CRC)

  • T1 CRC refers to early-stage colorectal cancer where the tumor has invaded the submucosa but has not yet spread further.
  • It is subdivided into superficial submucosal invasive cancer (s-SMIC) and deep submucosal invasive cancer (d-SMIC) based on the depth of invasion.
  • s-SMIC: Less invasive; better prognosis.
  • d-SMIC: More invasive; higher risk of lymphovascular invasion and metastasis.

Endoscopic Submucosal Dissection (ESD)

  • ESD is a minimally invasive endoscopic technique used to remove early-stage gastrointestinal tumors, including T1 CRC, en bloc (in one piece) to achieve clear margins.
  • It is increasingly being used as an alternative to primary surgery for patients with suspected T1 CRC, especially for those with s-SMIC.

Key Findings from the Study (2011–2022)

  1. Effectiveness of ESD:
  • ESD was more effective in achieving a free vertical margin (VM-R0) in suspected s-SMIC cases compared to d-SMIC cases.
  • The VM-R0 rate for suspected s-SMIC was 90.6%, while it was significantly lower for suspected d-SMIC at 55.4%.
  • The en bloc resection rate was also higher in s-SMIC (90.5%) compared to d-SMIC (61.9%).
  1. Challenges in d-SMIC:
  • For suspected d-SMIC cases, the VM-R0 rate particularly decreased for pT1Sm2-3 lesions (55.7%).
  • None of the investigated clinical or polyp-related features (age, sex, polyp location, size, morphology, and Hiroshima classification) could predict VM-R1 resections in d-SMIC cases.
  1. Adverse Events:
  • The adverse event rate was slightly higher in d-SMIC cases (5.8%) compared to s-SMIC cases (3.6%).
  1. Implications for Treatment:
  • The lower success rate of ESD (in terms of VM-R0) for d-SMIC highlights the need for careful patient selection.
  • For suspected d-SMIC cases, alternative treatment strategies, including surgery, may be more appropriate to ensure complete resection and reduce the risk of recurrence.

Clinical Significance

  • For s-SMIC, ESD is a highly effective and safe option, offering high rates of curative resection with minimal complications.
  • For d-SMIC, the lower VM-R0 rates suggest that ESD alone may not always be sufficient, and primary surgery may be considered for better oncological outcomes.

Future Perspectives (2026 and Beyond)

  • As ESD techniques continue to evolve, future studies may focus on improving the success rates for d-SMIC cases.
  • The development of advanced imaging techniques and predictive tools could help in better identifying patients who are suitable for ESD versus surgery.
  • Long-term follow-up data from ongoing or future studies (such as the one in 2026) will be crucial in determining the role of ESD in managing T1 CRC, particularly for d-SMIC cases.

Related Q&A

119

Novel Therapeutic approach for pancreatic cancer(GIE,Jan-2026)

The novel therapeutic approach for pancreatic cancer, as detailed in the study published in Gastrointestinal Endoscopy (GIE), January 2026, involves the combination of intratumoral phosphorus-32 (32P) implantation with...

120

Screening for Esophageal Cancer

Screening for esophageal cancer is a critical strategy to improve early detection and survival rates, given the disease's poor prognosis due to late-stage diagnosis. However, effective screening approaches...

121

Glecirasib with or without Cetuximab in previously treated CRC with KRAS mutation - Lancet Gastroenterol Hepatol

The study published in Lancet Gastroenterology & Hepatology investigates the efficacy and safety of glecirasib (JAB-21822), a novel covalent small molecule KRASG12C inhibitor, as monotherapy or in combination...

122

New Drugs for hepatobiliary Cancers - J of Hepatology - Jan.26

The treatment of hepatobiliary cancers, including hepatocellular carcinoma (HCC) and biliary tract cancer (BTC), is undergoing significant advancements with the development of novel drugs and therapeutic strategies. These...

123

Tumour Microenvironment in ICC

The tumor microenvironment (TME) in intrahepatic cholangiocarcinoma (iCCA) plays a pivotal role in tumor progression, immune evasion, and therapeutic resistance. iCCA is characterized by a highly complex and...

124

Chines Expert Consensus of GIST

The Chinese Expert Consensus on Diagnosis and Treatment of Small Gastrointestinal Stromal Tumors (GISTs) is a comprehensive guideline developed by the CSCO Gastrointestinal Stromal Tumor Committee in collaboration...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer